EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 3.0

Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment

Kristen King-Concialdi iD, Kathleen Beusterien, Steven S Senglaub iD, Oliver Will iD, Dena H Jaffe iD, Miraj Y Patel, Michael R Harrison

Patient Preference and Adherence · 2023-09 · Volume 17 · 2237-2248

DOI: 10.2147/ppa.s411751 ↗

At a glance

Journal article in Patient Preference and Adherence, 2023-09. Written by Kristen King-Concialdi and 6 co-authors. Institution: Real-World Evidence, Cerner Enviza, an Oracle Company, North Kansas City, MO, USA. Cited 9 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC 3.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

The evolving treatment landscape in muscle-invasive urothelial carcinoma creates challenges for clinicians and patients in selecting the most appropriate therapy. Here, we aimed to understand adjuvant treatment preferences among patients with muscle-invasive urothelial carcinoma who underwent radical resection, including tradeoffs between efficacy outcomes and toxicity risks. Patients and Methods: An observational, cross-sectional study utilizing a discrete choice experiment was conducted across the United States, United Kingdom, Canada, France, and Germany via a web-based survey. Patients ≥18 years of age who self-reported as having been diagnosed with muscle-invasive urothelial carcinoma were included. Patients indicated their preferences between hypothetical treatment profiles varying in eight attributes relating to efficacy, regimen, and side effects. Preference weights were estimated using hierarchical Bayesian logistic regression; relative attribute importance estimates were calculated.

Results

Overall, 207 patients were included (age ≥56 years, 65.7%; male, 54.1%). Patients chose adjuvant treatment 91.2% of the time vs no treatment. Prolonging overall survival from 25 to 78 months was most important, followed by reducing serious side effect risks. Increasing disease-free survival from 12 to 24 months was more important than decreasing risks of fatigue from 54% to 15% and nausea from 53% to 7%. Treatment with the shortest dosing regimen was more important for patients who received neoadjuvant chemotherapy vs patients who did not receive neoadjuvant chemotherapy; prolonging overall survival was more important than reducing the risk of a serious side effect in non-US patients; the opposite was found in the United States.

Conclusion

Patients with muscle-invasive urothelial carcinoma who underwent radical resection preferred adjuvant treatment over no treatment regardless of side effects. Patients prioritized overall survival improvements followed by a reduced side effect profile.

Subjects

Author keywords

bladder cancerdiscrete choice experimentmuscle-invasive urothelial carcinomapatient treatment preferences

Authors and institutions

  • Real-World Evidence, Cerner Enviza, an Oracle Company, North Kansas City, MO, USA.
  • Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.
  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.

ORCID profiles: Kristen King-Concialdi, Steven S Senglaub, Oliver Will, Dena H Jaffe

Cite

APA

King-Concialdi, K., Beusterien, K., Senglaub, S. S., Will, O., Jaffe, D. H., Patel, M. Y., & Harrison, M. R. (2023). Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment. Patient Preference and Adherence, Volume 17, 2237-2248. https://doi.org/10.2147/ppa.s411751

Vancouver

King-Concialdi K, Beusterien K, Senglaub SS, Will O, Jaffe DH, Patel MY, et al. Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment. Patient Preference and Adherence. 2023;Volume 17:2237-2248. doi:10.2147/ppa.s411751

BibTeX
@article{KingConcialdi2023,
  author = {King-Concialdi, Kristen and Beusterien, Kathleen and Senglaub, Steven S and Will, Oliver and Jaffe, Dena H and Patel, Miraj Y and Harrison, Michael R},
  title = {Patient Preferences for Adjuvant Treatment in Muscle-Invasive Urothelial Carcinoma: A Multi-Country Discrete Choice Experiment},
  journal = {Patient Preference and Adherence},
  year = {2023},
  volume = {Volume 17},
  pages = {2237--2248},
  doi = {10.2147/ppa.s411751}
}
Start for free →